PMID- 22031314
OWN - NLM
STAT- MEDLINE
DCOM- 20111215
LR  - 20220317
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 136
IP  - 5
DP  - 2011 Nov
TI  - Effect of ischemic time, fixation time, and fixative type on HER2/neu 
      immunohistochemical and fluorescence in situ hybridization results in breast 
      cancer.
PG  - 754-61
LID - 10.1309/AJCP99WZGBPKCXOQ [doi]
AB  - Accurate determination of HER2/neu status in breast carcinoma is essential. 
      Alteration of preanalytic variables is known to affect HER2/neu results. American 
      Society of Clinical Oncology (ASCO) and the College of American Pathologists 
      (CAP) issued guidelines to standardize fixation for increased HER2/neu accuracy. 
      We studied the effects of changing preanalytic variables on HER2/neu 
      immunohistochemical and fluorescence in situ hybridization (FISH) results in a 
      known HER2/neu+ invasive carcinoma. The clinical specimen was processed according 
      to ASCO/CAP guidelines, with remaining tumor stored fresh without any fixatives 
      for 4 days at 4 degrees C and cut into core biopsy-sized pieces. Each was fixed in 10% 
      formalin, 15% formalin, Pen-Fix (Richard-Allan Scientific, Kalamazoo, MI), Bouin 
      solution, Sakura molecular fixative (Sakura Tissue-Tek Xpress, Torrance, CA), or 
      zinc formalin for 0 to 168 hours. Immunohistochemical studies and FISH were 
      performed. Compared with the clinical specimen, the samples showed no tumor 
      degradation or marked difference by immunohistochemical studies, except the 
      1-hour 10% formalin and Bouin samples, or FISH, except the Bouin-fixed samples. 
      Our study demonstrates that HER2/neu results remain accurate beyond 
      ASCO/CAP-recommended preanalytic variables, with the exception of Bouin solution 
      for FISH analysis.
FAU - Moatamed, Neda A
AU  - Moatamed NA
AD  - Dept. of Pathology and Laboratory Medicine, David Geffen School of Medicine, 
      University of California-Los Angeles, 10833 Le Conte Ave CHS, Los Angeles, CA 
      90095, USA.
FAU - Nanjangud, Gouri
AU  - Nanjangud G
FAU - Pucci, Richard
AU  - Pucci R
FAU - Lowe, Alarice
AU  - Lowe A
FAU - Shintaku, I Peter
AU  - Shintaku IP
FAU - Shapourifar-Tehrani, Saeedeh
AU  - Shapourifar-Tehrani S
FAU - Rao, Nagesh
AU  - Rao N
FAU - Lu, David Y
AU  - Lu DY
FAU - Apple, Sophia K
AU  - Apple SK
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Fixatives)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*diagnosis/metabolism
MH  - Carcinoma, Ductal, Breast/*diagnosis/metabolism
MH  - Female
MH  - Fixatives
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/*metabolism
MH  - Tissue Fixation/*methods
EDAT- 2011/10/28 06:00
MHDA- 2011/12/16 06:00
CRDT- 2011/10/28 06:00
PHST- 2011/10/28 06:00 [entrez]
PHST- 2011/10/28 06:00 [pubmed]
PHST- 2011/12/16 06:00 [medline]
AID - 136/5/754 [pii]
AID - 10.1309/AJCP99WZGBPKCXOQ [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2011 Nov;136(5):754-61. doi: 10.1309/AJCP99WZGBPKCXOQ.